Search
forLearn
5 / 801 resultslearn TDM-105795
learn HT-B
learn TeraBond™ (Actera)
learn trimethicone
Research
5 / 1000+ results
research Human health impacts of drinking water (surface and ground) pollution Dakahlyia Governorate, Egypt
Removing trace elements from drinking water is essential for human safety.
research Melatonin induces a stimulatory action on the scrotal skin components of Soay ram in the non-breeding season
Melatonin stimulates the skin components of ram's scrotum during their non-breeding season.
research An Investigation of Keratin 15 Function by Small Interfering Ribonucleic Acid Technology
Keratin 15 affects cell behavior and characteristics in skin cells.
research Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells
Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
Community Join
5 / 1000+ resultscommunity I started rapidly diffuse thinning at 22. I'm 42 now and have as much hair as I did at 16. AMA
Hair loss treatments like finasteride, minoxidil, ketoconazole, PRP, and microneedling helped maintain hair for 20 years. Research and try evidence-based treatments for best results.
community How much do we know about PTD-DBM?
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Ordered PTD-DBM from tailor made
The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.